Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp442 | Osteoporosis: treatment | ECTS2013

Design of a prospective observational study to evaluate persistence and adherence during denosumab treatment, and patient characteristics in postmenopausal women with osteoporosis in routine clinical practice

Maurille Feudjo Tepie , Moller Gerd , Hadji Peyman , Ferreira Irene , Siddhanti Suresh , Boonen Stephen , Fahrleitner-Pammer Astrid , Papaioannou Nikos

Treatment of postmenopausal osteoporosis (PMO) has been traditionally hampered by poor persistence and adherence to short-term (≤1-monthly) medications. The efficacy of 6-monthly (Q6M) denosumab treatment has been proven in clinical trials, but effectiveness will be dependent on persistence and adherence in routine clinical practice. This study is designed to evaluate real-world persistence and adherence to denosumab, and to establish how this is best assessed in long-ac...

ba0001pp436 | Osteoporosis: treatment | ECTS2013

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

Recknor Christopher , Roux Christian , Ho Pei-Ran , Hall Jesse , Bone Henry , Bonnick Sydney , van den Bergh Joop , Ferreira Irene , Wagman Rachel , Brown Jacques P

: In osteoporosis, poor adherence to bisphosphonate (BP) therapy is common, and is associated with poor outcomes and increased treatment costs (Siris 2006; Recker 2005). Although compliance is improved with monthly vs weekly dosing (Reginster 2008), no evidence suggests cycling through BP agents offers therapeutic benefit, assessed by bone mineral density (BMD). In two randomized, open-label studies in postmenopausal women aged ≥55 years previously treated with, but subo...

ba0003pp357 | Osteoporosis: treatment | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...